Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patients’ needs in Europe for treating cancer. The Bengaluru facility was also approved for biosimilar Trastuzumab manufacturing. EMA renewed GMP certificates for Biocon’s facilities in Bengaluru and Malaysia. USFDA issued four observations after inspecting Biocon’s Andhra Pradesh plant, concluding inspections on June 21, 2024.
